159 related articles for article (PubMed ID: 36199143)
21. Diagnostic value of integrated
Zeng Y; Leng X; Liao H; Jiang G; Chen P
Prostate Int; 2022 Jun; 10(2):108-116. PubMed ID: 35510079
[TBL] [Abstract][Full Text] [Related]
22. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer.
Amin A; Blazevski A; Thompson J; Scheltema MJ; Hofman MS; Murphy D; Lawrentschuk N; Sathianathen N; Kapoor J; Woo HH; Chalasani V; Rasiah K; van Leeuwen PJ; Tang R; Cusick T; Stricker P; Emmett L
BJU Int; 2020 Apr; 125(4):515-524. PubMed ID: 31957122
[TBL] [Abstract][Full Text] [Related]
23. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
Baumann R; Koncz M; Luetzen U; Krause F; Dunst J
Strahlenther Onkol; 2018 Apr; 194(4):318-324. PubMed ID: 29181556
[TBL] [Abstract][Full Text] [Related]
24. Findings in 1,123 Men with Preoperative
Raveenthiran S; Yaxley WJ; Franklin T; Coughlin G; Roberts M; Gianduzzo T; Kua B; Samaratunga H; Delahunt B; Egevad L; Wong D; McEwan L; Brown N; Parkinson R; Esler R; Yaxley JW
J Urol; 2022 Mar; 207(3):573-580. PubMed ID: 34694140
[TBL] [Abstract][Full Text] [Related]
25. How accurate is
Erdem S; Simsek DH; Degirmenci E; Aydin R; Bagbudar S; Ozluk Y; Sanli Y; Sanli O; Ozcan F
Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
[TBL] [Abstract][Full Text] [Related]
26. Correlation between genomic index lesions and mpMRI and
Kesch C; Radtke JP; Wintsche A; Wiesenfarth M; Luttje M; Gasch C; Dieffenbacher S; Pecqueux C; Teber D; Hatiboglu G; Nyarangi-Dix J; Simpfendörfer T; Schönberg G; Dimitrakopoulou-Strauss A; Freitag M; Duensing A; Grüllich C; Jäger D; Götz M; Grabe N; Schweiger MR; Pahernik S; Perner S; Herpel E; Roth W; Wieczorek K; Maier-Hein K; Debus J; Haberkorn U; Giesel F; Galle J; Hadaschik B; Schlemmer HP; Hohenfellner M; Bonekamp D; Sültmann H; Duensing S
Sci Rep; 2018 Nov; 8(1):16708. PubMed ID: 30420756
[TBL] [Abstract][Full Text] [Related]
27. Residual γH2AX foci after ex vivo irradiation of patient samples with known tumour-type specific differences in radio-responsiveness.
Menegakis A; De Colle C; Yaromina A; Hennenlotter J; Stenzl A; Scharpf M; Fend F; Noell S; Tatagiba M; Brucker S; Wallwiener D; Boeke S; Ricardi U; Baumann M; Zips D
Radiother Oncol; 2015 Sep; 116(3):480-5. PubMed ID: 26297183
[TBL] [Abstract][Full Text] [Related]
28. Dual time point imaging of staging PSMA PET/CT quantification; spread and radiomic analyses.
Aksu A; Vural Topuz Ö; Yılmaz G; Çapa Kaya G; Yılmaz B
Ann Nucl Med; 2022 Mar; 36(3):310-318. PubMed ID: 34988888
[TBL] [Abstract][Full Text] [Related]
29. Residual gammaH2AX foci in head and neck squamous cell carcinomas as predictors for tumour radiosensitivity: Evaluation in pre-clinical xenograft models and clinical specimens.
Meneceur S; Löck S; Gudziol V; Hering S; Bütof R; Rehm M; Baumann M; Krause M; von Neubeck C
Radiother Oncol; 2019 Aug; 137():24-31. PubMed ID: 31048234
[TBL] [Abstract][Full Text] [Related]
30. Potential Impact of
Calais J; Kishan AU; Cao M; Fendler WP; Eiber M; Herrmann K; Ceci F; Reiter RE; Rettig MB; Hegde JV; Shaverdian N; King CR; Steinberg ML; Czernin J; Nickols NG
J Nucl Med; 2018 Nov; 59(11):1714-1721. PubMed ID: 29653978
[TBL] [Abstract][Full Text] [Related]
31. PSMA uptake on [68Ga]-PSMA-11-PET/CT positively correlates with prostate cancer aggressiveness.
Chen M; Qiu X; Zhang Q; Zhang C; Zhou YH; Zhao X; Fu Y; Wang F; Guo H
Q J Nucl Med Mol Imaging; 2022 Mar; 66(1):67-73. PubMed ID: 31359744
[TBL] [Abstract][Full Text] [Related]
32. Pilot study of the diagnostic utility of
Vlachostergios PJ; Niaz MJ; Thomas C; Christos PJ; Osborne JR; Margolis DJA; Khani F; Bander NH; Scherr DS; Tagawa ST
Prostate; 2022 Mar; 82(4):483-492. PubMed ID: 34985786
[TBL] [Abstract][Full Text] [Related]
33. Incremental Impact of [
Szigeti F; Schweighofer-Zwink G; Meissnitzer M; Hauser-Kronberger C; Hitzl W; Kunit T; Forstner R; Pirich C; Beheshti M
Mol Imaging Biol; 2022 Feb; 24(1):50-59. PubMed ID: 34519966
[TBL] [Abstract][Full Text] [Related]
34.
Liu C; Liu T; Zhang Z; Zhang N; Du P; Yang Y; Liu Y; Yu W; Li N; Gorin MA; Rowe SP; Zhu H; Yan K; Yang Z
J Nucl Med; 2020 Sep; 61(9):1314-1319. PubMed ID: 32034111
[TBL] [Abstract][Full Text] [Related]
35. Prospective comparison of whole-body MRI and
Sawicki LM; Kirchner J; Buddensieck C; Antke C; Ullrich T; Schimmöller L; Boos J; Schleich C; Schaarschmidt BM; Buchbender C; Heusch P; Rabenalt R; Albers P; Antoch G; Müller HW; Hautzel H
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1542-1550. PubMed ID: 30879122
[TBL] [Abstract][Full Text] [Related]
36. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
[TBL] [Abstract][Full Text] [Related]
37. Gallium 68 PSMA-11 PET/MR Imaging in Patients with Intermediate- or High-Risk Prostate Cancer.
Park SY; Zacharias C; Harrison C; Fan RE; Kunder C; Hatami N; Giesel F; Ghanouni P; Daniel B; Loening AM; Sonn GA; Iagaru A
Radiology; 2018 Aug; 288(2):495-505. PubMed ID: 29786490
[TBL] [Abstract][Full Text] [Related]
38. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.
Afshar-Oromieh A; Hetzheim H; Kratochwil C; Benesova M; Eder M; Neels OC; Eisenhut M; Kübler W; Holland-Letz T; Giesel FL; Mier W; Kopka K; Haberkorn U
J Nucl Med; 2015 Nov; 56(11):1697-705. PubMed ID: 26294298
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic performance of
Gao J; Zhang C; Zhang Q; Fu Y; Zhao X; Chen M; Zhang B; Li D; Shi J; Wang F; Guo H
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1531-1541. PubMed ID: 31025048
[TBL] [Abstract][Full Text] [Related]
40. High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with
Werner RA; Habacha B; Lütje S; Bundschuh L; Higuchi T; Hartrampf P; Serfling SE; Derlin T; Lapa C; Buck AK; Essler M; Pienta KJ; Eisenberger MA; Markowski MC; Shinehouse L; AbdAllah R; Salavati A; Lodge MA; Pomper MG; Gorin MA; Bundschuh RA; Rowe SP
Mol Imaging; 2022; 2022():7056983. PubMed ID: 35283693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
